Literature DB >> 9711920

Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.

V Wright-Browne1, A M Schnee, M A Jenkins, P F Thall, B B Aggarwal, M Talpaz, Z Estrov.   

Abstract

Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymphocytes produce various cytokines that may provide the cells with a proliferative advantage, cytokine concentrations in serum samples taken from IM patients were measured in order to identify the cytokines responsible for the clinical manifestations of the disease. The concentrations of interleukin-1beta (IL-1beta), IL-2, IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), and lymphotoxin (LT) were measured using an enzyme-linked immunosorbent assay (ELISA) in serum obtained from 14 IM patients during the acute phase of the disease and during convalescence, 5 patients with identical clinical manifestations who did not have IM (sick controls), and 11 healthy volunteers. It was found that the serum levels of TNF-alpha and IL-6 were significantly high in patients with acute IM compared with the serum levels in healthy individuals (P = 0.008 and P < 0.001, respectively) but returned to normal at convalescence (P = 0.009 and P = 0.005 respectively). However, whereas TNF-alpha concentrations were significantly higher (P = 0.04) in patients with acute IM than in the sick controls, no significant difference in IL-6 concentrations was found between the two groups of patients. Changes in IL-10 concentration were not statistically significant, and IL-1beta, IL-2, IL-8, and LT were detected only sporadically. The data in this study suggest that TNF-alpha may have a specific role in causing the clinical manifestations of IM. Further studies should determine the clinical significance of TNF-alpha inhibition in IM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711920     DOI: 10.3109/10428199809057570

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function.

Authors:  Jordan S Orange; Sumita Roy-Ghanta; Emily M Mace; Saumya Maru; Gregory D Rak; Keri B Sanborn; Anders Fasth; Rushani Saltzman; Allison Paisley; Linda Monaco-Shawver; Pinaki P Banerjee; Rahul Pandey
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

3.  Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment.

Authors:  Ismail Sari; Merih Birlik; Servet Akar; Fatos Onen; Aydanur Kargi; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2008-11-26       Impact factor: 2.631

Review 4.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

5.  Common Respiratory Tract Infections as Psychological Entities: A Review of the Mood and Performance Effects of Being Ill.

Authors:  Tania Mahoney; Peter Ball
Journal:  Aust Psychol       Date:  2011-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.